Ionis Pharmaceuticals, Inc. (IONS)

Market Cap	12.36B
Revenue (ttm)	966.96M
Net Income (ttm)	-256.34M
Shares Out	161.97M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,020,899
Open	77.15
Previous Close	77.21
Day's Range	74.49 - 78.00
52-Week Range	23.95 - 86.15
Beta	0.28
Analysts	Strong Buy
Price Target	83.64 (+9.58%)
Earnings Date	Feb 18, 2026

About IONS

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSE...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 1991
• Employees: 1,069
• Stock Exchange: NASDAQ
• Ticker Symbol: IONS
• Website: https://www.ionis.com

Financial Performance

In 2024, Ionis Pharmaceuticals's revenue was $705.14 million, a decrease of -10.48% compared to the previous year's $787.65 million. Losses were -$453.90 million, 23.9% more than in 2023.

Analyst Summary

According to 22 analysts, the average rating for IONS stock is "Strong Buy." The 12-month stock price target is $83.64, which is an increase of 9.58% from the latest price.

Price Target

$83.64

(9.58% upside)

Analyst Consensus: Strong Buy